Search research articles
Contact Us
Filters
Showing results (141-150 of 178) with videos related to
Page
of 18
Sort By:
Breast Cancer Research and Treatment
|
September 15, 2020
Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
E Montagna, E Pagan, V Bagnardi, et al.
British Journal of Cancer
|
November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
J Bernhard, D Zahrieh, J J Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2018
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
N C Turner, R S Finn, M Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
P Karlsson, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 14, 2007
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M Kaufmann, G von Minckwitz, H D Bear, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M Rabaglio, Z Sun, K N Price, et al.
Breast Cancer Research and Treatment
|
December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
J Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2022
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
L Gianni, C S Huang, D Egle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
M Colleoni, S Li, R D Gelber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 3, 2024
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
S Rusakiewicz, S Tyekucheva, S Tissot-Renaud, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 178) with videos related to
Sort By:
Page
of 18
Breast Cancer Research and Treatment
|
September 15, 2020
Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
E Montagna, E Pagan, V Bagnardi, et al.
British Journal of Cancer
|
November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
J Bernhard, D Zahrieh, J J Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2018
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
N C Turner, R S Finn, M Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
P Karlsson, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 14, 2007
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M Kaufmann, G von Minckwitz, H D Bear, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M Rabaglio, Z Sun, K N Price, et al.
Breast Cancer Research and Treatment
|
December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
J Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2022
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
L Gianni, C S Huang, D Egle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
M Colleoni, S Li, R D Gelber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 3, 2024
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
S Rusakiewicz, S Tyekucheva, S Tissot-Renaud, et al.
Page
of 18